NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global ... ( NEW YORK Nov. 4 /- NeoStem Inc. (NYSE...)

HOME >> MEDICINE >> TECHNOLOGY

NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations

Date:11/4/2009

NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), announced today that Edward C. Geehr, M.D. has been named to the Company's Board of Directors. Dr. Geehr brings extensive experience in developing and operating global biotechnology businesses.

Serving as Executive Vice President of Operations, Dr. Geehr was responsible for the global commercial operations of Abraxis Bioscience, a global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatment for cancer and other critical illnesses.

Previously Dr. Geehr served as President of Allez Spine, LLC, a developer, manufacturer and distributor of medical devices, and was a co-founder and executive chairman of IPC-The Hospitalist Company, which became a publicly traded company in 2008. A graduate of Yale University, Dr. Geehr received his Medical Degree from Duke University. He trained in Emergency Medicine at UCLA and subsequently obtained Board certification. He is the author of many scientific articles and books and held a faculty appointment at the University of California, San Francisco School of Medicine.

Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are extremely pleased that Dr. Geehr is joining our Board of Directors. His experience in the growing fields of molecular science and treatments for critical illnesses, combined with his leadership in developing and operating global biotechnology businesses, will expand the scientific and practical knowledge governing NeoStem's decision-making as we move into a new growth era as a result of our acquisition last week of China Biopharmaceuticals Holdings, Inc., which is anticipated to close before the end of this week."

Dr. Geehr stated, "I
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine technology :

1. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
2. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
3. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
4. Xytis Names Gordon H. Busenbark as Chief Financial Officer
5. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
6. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
7. California Cryobank Names Richard Jennings President of FamilyCord Division
8. Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO
9. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
10. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
11. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer

Post Your Comments:

NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global ...( NEW YORK Nov. 4 /- NeoStem Inc. (NYSE...),Health